RBC raises target for Regeneron stock to USD 810.00
Published on 10/13/2026 at 16:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and results date
- RBC lifted its Regeneron target from USD 737.00 to USD 810.00 on October 8, 2026.
- Regeneron reported USD 4.29 billion in second-quarter revenue, up 16.70 percent year over year.
- Regeneron stock was last at EUR 690.30 at Tradegate on October 13, 2026 at 12:16 p.m. CEST.
- Regeneron had a P/E ratio of 18.50 and a market capitalization of USD 76.8 billion on October 13, 2026.
RBC raised its price target for Regeneron from USD 737.00 to USD 810.00 on October 8, 2026, while keeping a Sector Perform rating, according to Yahoo Finance. Regeneron stock was last at EUR 690.30 on Tradegate on October 13, 2026 at 12:16 p.m. CEST.
RBC target reaches USD 810.00
The RBC move puts the new target USD 73.00 above the earlier USD 737.00 level. The company trades on Nasdaq under ticker REGN, as identified in Regeneron's scheduled-results release.
Second-quarter revenue rose 16.70 percent
Regeneron reported USD 4.29 billion in revenue for the second quarter of 2026, compared with USD 3.82 billion expected by analysts, according to MarketBeat. Revenue was up 16.70 percent from USD 3.68 billion in the comparable period, giving the latest operating update a clear growth measure.
Price sits below yearly high
The current US-dollar range runs from USD 553.87 to USD 859.34 for the 52-week period ending October 13, 2026. Regeneron's USD 76.8 billion market capitalization and P/E ratio of 18.50 place the stock among large biotechnology companies, while its latest US quote stood at USD 745.93 at 10:06 a.m. ET on October 13, 2026.
Valuation and October 30 results
Regeneron is scheduled to report third-quarter 2026 results before the US market opens on October 30, 2026. The company said the conference call will begin at 8:30 a.m. ET, according to its release. That date gives the market a defined next checkpoint after the recent target revisions.
Comparison with peers
Regeneron: P/E 18.50, market capitalization USD 76.8 billion.
Eli Lilly and Company (NYSE, USD): P/E 39.48, market capitalization USD 1.1 trillion.
Vertex Pharmaceuticals (Nasdaq, USD): P/E 28.94, market capitalization USD 125.6 billion.
Trading remains tied to target and results
For investors, the key tension is visible in the gap between the USD 810.00 RBC target and the October 30 reporting date. The target revision adds a fresh valuation reference, while the next earnings release will test whether second-quarter revenue growth continues into the third quarter.
Market context: Market report Nasdaq Composite.
More news and analyses on Regeneron stock.
Regeneron stock at a glance
- Company: Regeneron Pharmaceuticals, Inc.
- ISIN: US75886F1075
- Ticker: REGN
- Primary exchange: Nasdaq
- Price Tradegate as of October 13, 2026 at 12:16 p.m. CEST: EUR 690.30
- Market capitalization: USD 76.8 billion (as of October 13, 2026)
- 52-week range: USD 553.87-859.34 (as of October 13, 2026)
- Sector / Industry: Healthcare / Biotechnology
